Alfaxalone is a neuroactive steroid that acts as a positive allosteric modulator of GABA receptors, causing hyperpolarization of the neuron and producing a strong anesthetic effect. 24 This compound has been reintroduced into the veterinary market (Jurox, Kansas City, MO) after reformulation with hydroxypropyl β-cyclodextrin and is licensed in several countries for use as an anesthetic induction and maintenance agent in dogs and cats. In 2017, the alfaxalone license in the United Kingdom was extended to include the induction of anesthesia in rabbits. Although its licensing around the world is predominantly for intravenous use, the formulation of the drug allows for it to be used intramuscularly. 13 Alfaxalone can be administered through several parenteral routes and does not cause tissue irritation when extravasation occurs, thus offering a distinct advantage over other anesthetics, namely propofol. 17 Alfaxalone has been safely used in a variety of species for intramuscular administration. In cats, a pharmacokinetic analysis comparing intramuscular with intravenous use showed that intramuscular administration offered high bioavailability (94.7%) and a halflife that was roughly 2.5 times greater than of intravenous use. 18 Intramuscular administration resulted in deep sedation that lasted from 10 to 45 min. 18 In dogs, intramuscular alfaxalone produced consistent and stable sedation, with dose-dependent cardiorespiratory depression. 22 In pigs, intramuscular alfaxalone combined with dexmedetomidine produced smoother induction and deeper sedation than the combination of ketamine and dexmedetomidine. 19 A study in cats comparing intramuscular dexmedetomidine and butorphanol combined with either alfaxalone or ketamine showed that alfaxalone provided effective sedation for castration procedures and yielded a smoother recovery than ketamine. 14 In addition, alfaxalone has been investigated through several administration routes as an anesthetic option in small mammals including rats, ferrets, and guinea pigs. 2-4,9,15 Several studies have investigated the intravenous use of alfaxalone in rabbits. 8,11,23 However, only 2 studies to date have investigated the intramuscular use of alfaxalone in rabbits. One of these studies identified the potential for alfaxalone as an intramuscular sedative and induction agent in wild rabbits. 16 The other study found that 6 mg/kg alfaxalone administered intramuscularly produced smooth and consistent sedation with minimal side effects; given these results, we chose this dose of alfaxalone for investigation in our current study. 13 Previously published injectable rabbit sedation protocols use a range of sedatives, including ketamine, opioids, α2 agonists, and benzodiazepines. 6,7 One common injectable combination that is used in rabbits is ketamine-xylazine, but intramuscular injection of ketamine is reported to be painful, 5 thus warranting investigation into alternative injectable anesthetics. The studies to date have described the safety of intramuscular alfaxalone alone in rabbits, de...